# IMP1734

Source: https://onco.cc/drugs/imp1734/  
OnCo record `imp1734` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EIK1003, formerly IMP1734, is an experimental pill that blocks the PARP1 DNA-repair enzyme.

## Summary

Eikon identifies EIK1003 as the former IMP1734 programme. NCT06253130 is a recruiting phase 1/2 study in advanced solid tumours. The sponsor describes PARP1 selectivity; this does not establish clinical superiority or an approved biomarker population. The asset and its licensing alias are one programme, distinct from EIK1004/IMP1707 and the WRN inhibitor EIK1005.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-10-06
- Also known as: EIK1003
- Tags: pipeline; ctgov-ingest; registry-only
- Code: IMP1734
- Modality: Small-molecule inhibitor
- Mechanism: PARP1-selective inhibitor and trapper, licensed as EIK1003.

## Sources

- ClinicalTrials.gov: trials of IMP1734: https://clinicaltrials.gov/search?intr=IMP1734
- ClinicalTrials.gov NCT06253130: https://clinicaltrials.gov/study/NCT06253130
- Eikon licensing identities: https://www.eikontx.com/news/eikon-therapeutics-to-provide-corporate-updates-at-the-42nd-annual-j-p-morgan-healthcare-conference/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/)
- trials: [A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06253130/)

---
JSON: https://onco.cc/api/v1/entities/imp1734.json